Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus
<p>Human serum paraoxonase contributes to the anti-atherogenic effect of high-density lipoprotein cholesterol (HDL-C) and has been shown to protect both low-density lipoprotein cholesterol (LDL-C) and HDL-C against lipid peroxidation. We investigated the effects of rosiglitazone on paraoxonase...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Associação Brasileira de Divulgação Científica
2013-01-01
|
| Series: | Brazilian Journal of Medical and Biological Research |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2013005032818 |
| _version_ | 1818173693821452288 |
|---|---|
| author | Y. Atamer A. Atamer A.S. Can A. Hekimoğlu N. Ilhan N. Yenice Y. Koçyiğit |
| author_facet | Y. Atamer A. Atamer A.S. Can A. Hekimoğlu N. Ilhan N. Yenice Y. Koçyiğit |
| author_sort | Y. Atamer |
| collection | DOAJ |
| description | <p>Human serum paraoxonase contributes to the anti-atherogenic effect of high-density lipoprotein cholesterol (HDL-C) and has been shown to protect both low-density lipoprotein cholesterol (LDL-C) and HDL-C against lipid peroxidation. We investigated the effects of rosiglitazone on paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus [50 patients (30 males, 20 females); mean±SD age: 58.7±9.2 years, body mass index: 28.2±4.1 kg/m<sup>2</sup>], in whom glucose control could not be achieved despite treatment with metformin, sulphonylurea, and/or insulin. The patients were given 4 mg/day rosiglitazone for 3 months in addition to their usual treatment. Serum paraoxonase activity, malondialdehyde, homocysteine, and lipid profile were measured at the time of initiation and at the end of therapy with rosiglitazone. After rosiglitazone therapy, serum levels of HDL-C, apolipoprotein A-1, and paraoxonase activity increased significantly (P<0.05) and malondialdehyde, homocysteine, lipoprotein(a), and glucose levels decreased significantly (P<0.05), but no significant changes in levels of total cholesterol and apolipoprotein B were observed. Triglyceride levels also increased significantly (P<0.05). Rosiglitazone treatment led to an improvement in glycemic control and to an increase in paraoxonase activity and HDL-C levels. Although rosiglitazone showed favorable effects on oxidant/antioxidant balance and lipid profile, further studies are needed to determine the effect of rosiglitazone on cardiovascular risk factors and cardiovascular morbidity and mortality.</p> |
| first_indexed | 2024-12-11T19:32:34Z |
| format | Article |
| id | doaj.art-4a26f8376cf8464298f3722ae402b1c0 |
| institution | Directory Open Access Journal |
| issn | 0100-879X 1414-431X |
| language | English |
| last_indexed | 2024-12-11T19:32:34Z |
| publishDate | 2013-01-01 |
| publisher | Associação Brasileira de Divulgação Científica |
| record_format | Article |
| series | Brazilian Journal of Medical and Biological Research |
| spelling | doaj.art-4a26f8376cf8464298f3722ae402b1c02022-12-22T00:53:13ZengAssociação Brasileira de Divulgação CientíficaBrazilian Journal of Medical and Biological Research0100-879X1414-431X2013-01-01ahead000000Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitusY. AtamerA. AtamerA.S. CanA. HekimoÄŸluN. IlhanN. YeniceY. KoçyiÄŸit<p>Human serum paraoxonase contributes to the anti-atherogenic effect of high-density lipoprotein cholesterol (HDL-C) and has been shown to protect both low-density lipoprotein cholesterol (LDL-C) and HDL-C against lipid peroxidation. We investigated the effects of rosiglitazone on paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus [50 patients (30 males, 20 females); mean±SD age: 58.7±9.2 years, body mass index: 28.2±4.1 kg/m<sup>2</sup>], in whom glucose control could not be achieved despite treatment with metformin, sulphonylurea, and/or insulin. The patients were given 4 mg/day rosiglitazone for 3 months in addition to their usual treatment. Serum paraoxonase activity, malondialdehyde, homocysteine, and lipid profile were measured at the time of initiation and at the end of therapy with rosiglitazone. After rosiglitazone therapy, serum levels of HDL-C, apolipoprotein A-1, and paraoxonase activity increased significantly (P<0.05) and malondialdehyde, homocysteine, lipoprotein(a), and glucose levels decreased significantly (P<0.05), but no significant changes in levels of total cholesterol and apolipoprotein B were observed. Triglyceride levels also increased significantly (P<0.05). Rosiglitazone treatment led to an improvement in glycemic control and to an increase in paraoxonase activity and HDL-C levels. Although rosiglitazone showed favorable effects on oxidant/antioxidant balance and lipid profile, further studies are needed to determine the effect of rosiglitazone on cardiovascular risk factors and cardiovascular morbidity and mortality.</p>http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2013005032818RosiglitazoneDiabetes mellitus type 2ParaoxonaseLipoproteinsHomocysteineLipid peroxidation |
| spellingShingle | Y. Atamer A. Atamer A.S. Can A. Hekimoğlu N. Ilhan N. Yenice Y. Koçyiğit Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus Brazilian Journal of Medical and Biological Research Rosiglitazone Diabetes mellitus type 2 Paraoxonase Lipoproteins Homocysteine Lipid peroxidation |
| title | Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus |
| title_full | Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus |
| title_fullStr | Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus |
| title_full_unstemmed | Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus |
| title_short | Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus |
| title_sort | effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus |
| topic | Rosiglitazone Diabetes mellitus type 2 Paraoxonase Lipoproteins Homocysteine Lipid peroxidation |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2013005032818 |
| work_keys_str_mv | AT yatamer effectsofrosiglitazoneonserumparaoxonaseactivityandmetabolicparametersinpatientswithtype2diabetesmellitus AT aatamer effectsofrosiglitazoneonserumparaoxonaseactivityandmetabolicparametersinpatientswithtype2diabetesmellitus AT ascan effectsofrosiglitazoneonserumparaoxonaseactivityandmetabolicparametersinpatientswithtype2diabetesmellitus AT ahekimoaylu effectsofrosiglitazoneonserumparaoxonaseactivityandmetabolicparametersinpatientswithtype2diabetesmellitus AT nilhan effectsofrosiglitazoneonserumparaoxonaseactivityandmetabolicparametersinpatientswithtype2diabetesmellitus AT nyenice effectsofrosiglitazoneonserumparaoxonaseactivityandmetabolicparametersinpatientswithtype2diabetesmellitus AT ykoayiayit effectsofrosiglitazoneonserumparaoxonaseactivityandmetabolicparametersinpatientswithtype2diabetesmellitus |